1. Legal and Ethical Issues in Human Genetics

Legal and Ethical Issues in Human Genetics

Laurie Demmer, MD
December 13, 2005

(c) 2005, Laurie Ann Demmer, M.D.

2. Confidentiality

Confidentiality

• Physicians are required by law to hold what they learn from their patients in confidence.
• BUT genetic information is FAMILY-CENTERED by nature
• When is it ok to breach confidentiality?

(c) 2005, Laurie Ann Demmer, M.D.
3. Malpractice Law

**Malpractice Law**

- Failure to alert patients about relevant genetic tests may lead to wrongful birth lawsuits.
- Down Syndrome and amniocentesis
- Neural tube defect and alpha-fetal protein
- Canavan screening in Ashkenazi Jewish
- Cystic Fibrosis screening offered to all couples considering a pregnancy

(c) 2005, Laurie Ann Demmer, M.D.

4. Genetic Discrimination

**Genetic Discrimination**

- Concern that genetic information will be used to deny or limit access to insurance and employment.
- Federal (HIPPA) and state laws in place to provide protection for patients in group health plans.
- Current laws do not address discrimination by Life Insurance Companies

(c) 2005, Laurie Ann Demmer, M.D.
5. Genetic Discrimination

Genetic Discrimination

- EEOC issued a guideline in 1995 interpreting the American with Disabilities Act as forbidding employers from using genetic information in hiring or promotion.
- Despite widespread fears, there is little evidence that predictive genetic information has yet been used to deny health insurance or employment.

(c) 2005, Laurie Ann Demmer, M.D.

6. Regulation of Human Genome Research

Regulation of Human Genome Research

- Intellectual Property: who owns the tissue samples: patient vs. laboratory
- To whom does “The Human Genome” belong?
  - Individuals
  - Family
  - Society

(c) 2005, Laurie Ann Demmer, M.D.
7. Gene Patents

**Gene Patents**

- The creation of intellectual property based on DNA sequence information
- Patents on human genes “offend the principle of the sanctity of human life”
- Biotechnology industry: patent protection is “an essential element of the commercialization process”.

(c) 2005, Laurie Ann Demmer, M.D.

8. Ethical Challenges in Genetic Testing

**Ethical Challenges in Genetic Testing**

- Rapid advances in genetic technology and the Human Genome Project are predicted to revolutionize current medical practice.
- Are physicians/geneticists ordering genetic tests aware of the relevant ethical principles and legal obligations resulting from this new technology?

(c) 2005, Laurie Ann Demmer, M.D.
Views on Genetic Testing

I feel comfortable with my knowledge of available genetic tests 18%

I have a standard for deciding when patients need to be informed about the option of genetic testing 28%

I am comfortable counseling patients before and after genetic testing 17%

(c) 2005, Laurie Ann Demmer, M.D.

Autonomy

*Patients facing choices regarding genetic testing are entitled to exercise personal autonomy free from undue pressures and equipped with adequate information to understand the implications for themselves and others of the available options.

* B. Dickens, 1996

(c) 2005, Laurie Ann Demmer, M.D.
11. Beneficence / Nonmaleficence

**Beneficence / Nonmaleficence**

- **Beneficence**: The duty to do and to maximize good
- **Nonmaleficence**: the duty to do no harm or to minimize harm in pursuing a greater good

(c) 2005, Laurie Ann Demmer, M.D.

12. Legal Responsibilities of Health Care Providers

**Legal Responsibilities of Health Care Providers**

- **Patient-physician confidentiality** ensures maintenance of privacy for the patient
- Known exceptions to the protection of confidentiality of medical information:
  - Tarasoff case (1976)-threat of violence

(c) 2005, Laurie Ann Demmer, M.D.
13. Case 3: Familial Adenomatous Polyposis

Case 3: Familial Adenomatous Polyposis

• RM is a 47 year old man has been diagnosed with FAP and colon cancer. He undergoes colectomy.
• RM has 6 children aged 4-25. He and his family are referred for genetic counseling.

(c) 2005, Laurie Ann Demmer, M.D.

14. Familial Adenomatous Polyposis

Familial Adenomatous Polyposis

• 1% of colon cancer
• Incidence 1/10,000
• >100 polyps develop diffusely throughout the colon
• 50% of patients develop adenomas by age 15
• 100% of patients develop cancer by age 40

(c) 2005, Laurie Ann Demmer, M.D.
15. Genetic testing for FAP

**Genetic testing for FAP**

- Gene Sequencing: 90% sensitive
- Aggressive gene testing in at-risk individuals
- TEST MINORS
- Aggressive colonic screening beginning at puberty
- Colectomy recommended for affected pts

(c) 2005, Laurie Ann Demmer, M.D.

16. Case 3: Familial Adenomatous Polyposis

**Case 3: Familial Adenomatous Polyposis**

- RM is a 47 year old man has been diagnosed with FAP and colon cancer. He undergoes colectomy.
- RM has 6 children aged 4-25. He and his family are referred for genetic counseling.
- He cancels the first appointment and ‘no shows’ the second. The third appt he came to the hospital, but then left the parking lot before entering the building.

(c) 2005, Laurie Ann Demmer, M.D.
17. Ethical Principles of Concern:

**Ethical Principles of Concern:**

* Privacy (patient)
* Duty to warn (children)
* Right not to know


**Duty to Warn Third Parties

* In 1954 a man dies at age 45 of complications of colon cancer. He has two daughters, ages 17 and 10.
* Twenty-six years later (1980), the younger daughter is diagnosed with metastatic colon carcinoma and Familial Adenomatous Polyposis.
19. Duty to Warn Third Parties

**Safer v. Pack (1996)**

- She obtains her father’s medical records and learns that he also was diagnosed with Familial Adenomatous Polyposis.
- She sues her father’s doctor’s estate (Dr. Pack died in 1969) for ‘violation of a duty to warn, failing to inform her of a foreseeable, avoidable risk’.

(c) 2005, Laurie Ann Demmer, M.D.

20. Duty to warn third parties, cont.

**Duty to warn third parties, cont.**

- She alleged that
  - FAP invariably leads to colon cancer
  - Dr. Pack knew of the hereditary nature of her father’s illness
  - Dr. Pack was ‘required by the standards prevailing at the time to warn individuals at risk so that they could seek early exam, detection and treatment’.

(c) 2005, Laurie Ann Demmer, M.D.
Duty to warn third parties, cont.

- Trial court dismissed the claim on the grounds that Dr. Pack had no legal duty to warn a patient’s child of a genetic risk
- Unlike contagious risk, or risk of harm, genetic risk was already present within the child
- the child did not have a patient-physician relationship with Dr. Pack

(c) 2005, Laurie Ann Demmer, M.D.

Duty to warn third parties, cont.

- In appeal, the superior court of NJ reversed the lower court’s decision
  - lower court erred in determining that the disease was unavoidable and unforeseeable
  - genetically transmissible condition is sufficiently similar to a contagious disease
    - individual is easily identified
    - substantial future harm may be averted or minimized by a timely and effective warning

(c) 2005, Laurie Ann Demmer, M.D.
Ethical Issues to Consider:

- **Patient confidentiality** (was her father unaware of genetic implications of his illness or did he choose not to tell them?)
- **Duty to warn**...can physicians get in trouble for breaching patient confidentiality?
- ASHG is calling for ‘legal privilege’ for physicians: to be given a discretionary right to disclose genetic info to at-risk relatives without incurring liability

(c) 2005, Laurie Ann Demmer, M.D.

Genetic Testing in Minors

**Genetic Testing in Minors**

- **Carrier testing**: wait until the child is old enough to decide for him/herself if knowledge of carrier testing is desired (privacy, non-maleficence)

- **Pre-dispositional testing**: consider testing if a **defined medical benefit** can be seen during childhood (beneficence)
  - retinoblastoma, FAP, VHL: childhood tumors can be screened for, improving survival

(c) 2005, Laurie Ann Demmer, M.D.
25. Genetic Testing in Minors

**Genetic Testing in Minors**

- **Pre-symptomatic testing for late onset diseases:** wait until child is old enough to decide for him/herself if knowledge of genetic status is desired. (privacy, non-maleficence)
- **Pre-symptomatic testing for childhood onset diseases:** ???

(c) 2005, Laurie Ann Demmer, M.D.

26. Friedreich Ataxia Case 1

**Friedreich Ataxia Case 1**

- JJ is a 9 year old boy who presents with tremors and unsteady gait.
- FRDA testing reveals two expanded alleles, confirming the diagnosis of Friedreich Ataxia (FA).
- FA is an Aut. Recessive progressive neurological disorder where pts are usually wheelchair bound by about age 18.

(c) 2005, Laurie Ann Demmer, M.D.
Freidreich Ataxia Case

Freidreich Ataxia Case

- JJ has 4 younger siblings between the ages of 8 years and 22 months.
- Parents want pre-symptomatic testing for the younger siblings.
- What are the pros and cons of testing the siblings at this time?

(c) 2005, Laurie Ann Demmer, M.D.

Issues to consider:

Issues to consider:

- What are the rights of the children? Can parents speak for them?
- Is there any point to doing testing if this is an untreatable condition?
- Do you have to order a genetic test just because parents request it?
- Are you worried that pre-symptomatic children will be treated differently by the parents than unaffected children?

(c) 2005, Laurie Ann Demmer, M.D.
29. Case: Hemophilia in the family?

**Case: Hemophilia in the family?**

- A 30 year old woman, AP, is shown by direct DNA testing to be a carrier of severe Factor VIII deficiency after losing her newborn son to an intracranial hemorrhage.
- AP has 2 younger sisters and one healthy brother. Their mother who died of alcohol-related liver disease was adopted and they had no further information re: family history.

(c) 2005, Laurie Ann Demmer, M.D.

30. Case: Hemophilia in the family?

**Case: Hemophilia in the family?**

- After discussing X-linked inheritance, recurrence risk and options for future pregnancies, you bring up the potential risk of either or both of AP’s sisters being carriers for hemophilia.
- AP is adamant that she hasn’t communicated with her sisters in 8 years and wasn’t about to start now, hemophilia or no!

(c) 2005, Laurie Ann Demmer, M.D.
31. Ethical Principles to Consider:

Ethical Principles to Consider:

- Privacy of AP’s genetic information
- Duty to disclose to family members

32. Case 1: CF Newborn Screening

Case 1: CF Newborn Screening

- 2/99: Mass. pilot program for CF newborn screening
- ‘opt out design’
- top 5% of daily IRT (immunoreactive trypsinogen) samples are screened for common mutations
- predicted to detect >98% of affected patients and ‘some’ carriers as well

(c) 2005, Laurie Ann Demmer, M.D.
Case 1: CF Newborn Screen

- HJ is a healthy newborn found to have elevated IRT on newborn screen
- Mutation analysis reveals one dF508
- Sweat test is negative, indicating HJ is a carrier
- Parents are seen in clinic, genetic counseling is provided, mutation analysis offered

(c) 2005, Laurie Ann Demmer, M.D.

Case 1: CF Newborn Screening

Reasons to offer mutation analysis to parents:
- to see if both are carriers (future reproductive decisions)
- to provide info to other relatives

Result: NEITHER PARENT IS A CARRIER OF THE dF508 MUTATION!!

(c) 2005, Laurie Ann Demmer, M.D.
Possible Explanations for Discrepancy:

1. Lab Reporting Error
2. Newborn Screen sample mix-up
3. Parental Sample mix-up
4. Baby is a new mutation for dF508
5. Non-paternity
6. Baby switch at birth

How to proceed...

1. Have the newborn screen and commercial lab re-run existing samples to check for reporting error
2. Ask for repeat samples from baby and parents to rule out sample mix-up
3. Ask the mother confidentially about the possibility of non-paternity
4. Offer the parents further DNA testing to differentiate between new mutation vs. non-paternity vs. baby switching
37. Ethical Principles of Concern:

**Ethical Principles of Concern:**

1. Duty to disclose vs. nonmaleficence: unsuspected paternity?

2. Autonomy/privacy: Can results be given to each parent privately or need it be done in context of family (as it was ordered)?

(c) 2005, Laurie Ann Demmer, M.D.

38. Case: Known but unknowing patients with Factor V Leiden Deficiency

**Case: Known but unknowing patients with Factor V Leiden Deficiency**

- Clinical molecular biologist calls for advice regarding 3 patients whose DNA he had been sent for CF carrier mutation analysis.
- Two years later, he used those samples (among others) to help design an assay for the common clotting disorder, Factor V Leiden deficiency.

(c) 2005, Laurie Ann Demmer, M.D.
Case: Known but unknowing patients with Factor V Leiden Deficiency

- He discovered, serendipitously, that these 3 patients carried the mutation and thus were at significant risk, compared to the general population, for clotting episodes.
- He asks your advice on how to proceed…. Should he… or you… inform the patients of the results of a test to which they did not consent?

(c) 2005, Laurie Ann Demmer, M.D.

Ethical Principles to consider:

- Privacy / autonomy of patients: right not to know
- Duty to disclose: prophylactic treatment is sometimes used in Factor V Leiden deficiency and can be life-saving

(c) 2005, Laurie Ann Demmer, M.D.
41. Case 2: 14 year old female with lack of pubertal development...

**Case 2: 14 year old female with lack of pubertal development**

- JJ was born the 6 pound product of an uncomplicated pregnancy.
- Puffy feet were noted at birth
- JJ had normal growth (height 50%) and normal development

(c) 2005, Laurie Ann Demmer, M.D.

42. Past Medical History

**Past Medical History**

- Supraventricular tachycardia and bicuspid aortic valve
- Hernia repair age 2
- Appendectomy age 11
- Ear tubes placed x3
- Healthy sister, maternal half sister and maternal half brother

(c) 2005, Laurie Ann Demmer, M.D.
Physical Exam

- Height 50%; Weight 75%
- Non-dysmorphic face
- Ears: borderline low-set
- Neck, chest, heart, abdomen, back, neuro: unremarkable
- Ext. exam negative for cubitus valgus or short metacarpals

(c) 2005, Laurie Ann Demmer, M.D.

Physical Exam, cont.

- Residual puffiness over proximal phalanx of all toes
- Genitalia: unambiguous female with Tanner I breast and no pubic or axillary hair

(c) 2005, Laurie Ann Demmer, M.D.
45. Work-up:

*Work-up:*

Chromosomes

Labs:

- Thyroid-normal
- LH-high
- FSH-very high
- Testosterone-low
- Estradiol-low
- DHEAS-normal

Pelvic Ultrasound:

Prepubertal uterus. No ovaries identified.

(c) 2005, Laurie Ann Demmer, M.D.

46. Follow-up

*Follow-up*

- What do you tell parents and patient about XY karyotype?
- If you leave out the part about the ‘Y’ chromosome, are they likely to hear it from someone else?
- Can you tell the patient and family that she has a form of Turner Syndrome and leave it at that?

(c) 2005, Laurie Ann Demmer, M.D.
47. Ethical Principles of Concern:

* Nonmaleficence
* Autonomy

(c) 2005, Laurie Ann Demmer, M.D.